dA-NHbenzylOCF3
Based on 1 Customer Validation
dA-NHbenzylOCF3 is a DNA-targeted radiosensitizer that enhances the sensitivity of tumor cells to X-rays via the dissociative electron attachment (DEA) mechanism. dA-NHbenzylOCF3 shows low cytotoxicity to normal cells and mainly localizes to the cytoplasm and nucleus after entering cells. dA-NHbenzylOCF3 exerts its radiosensitizing effect by inducing cell cycle arrest at the radiation-sensitive G2/M phase. dA-NHbenzylOCF3 can be used for radiosensitization research on malignant tumors such as prostate cancer and breast cancer.
For research use only. We do not sell to patients.
- Purity : 98.04%
- Formula: C18H19F3N6O4
- Molecular Weight:440.38
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
In Vitro
dA-NHbenzylOCF3 (0.001-100 µM; 48-72 h) exhibits low cytotoxicity against PC3, MCF-7 and HaCaT cells, with statistically significant decreases in cell viability observed only at 20 µM (PC3, 72 h) and 100 µM (all cell lines, 48/72 h)[1].
dA-NHbenzylOCF3 (20 µM; administered 48 h prior to irradiation with 1, 3, 4 Gy) significantly enhances the radiosensitivity of PC3 and MCF-7 cells to X-rays at a statistical level, with stronger activity against PC3 cells (an α elevation factor of 2.1 versus 1.5 for MCF-7 cells), and the dose enhancement factors are 1.30 (PC3) and 1.21 (MCF-7), respectively[1].
When combined with X-ray irradiation, dA-NHbenzylOCF3 (20 µM; treated for 48 h before 8 Gy irradiation; incubated for 24 h after irradiation) regulates the cell cycle progression of PC3 and MCF-7 cells, increases the proportion of cells in the radiation-sensitive G2/M phase, and this effect is more pronounced in PC3 cells[1].
dA-NHbenzylOCF3 (20-100 µM; 48 h) penetrates PC3 cells, localizes primarily in the cytoplasm (with a cytoplasm-to-nucleus ratio ranging from 26:1 to 22:1), and exists exclusively in the non-phosphorylated form[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC3 (human prostate cancer), MCF-7 (human breast cancer), HaCaT (immortalized human keratinocyte)
-
Concentration:0.001, 0.01, 0.1, 1, 10, 20, 100 µM
-
Incubation Time:48 h; 72 h
-
Result:Reduced PC3 cell viability to 86.3% (48 h) and 80.8% (72 h,) at 100 µM; reduced viability to 88.5% (72 h) at 20 µM.
Reduced MCF-7 cell viability to 91.9% (48 h) and 87.5% (72 h) at 100 µM.
Reduced HaCaT cell viability to 84.2% (48 h) and 76.3% (72 h) at 100 µM.
Caused no statistically significant viability reduction at lower tested concentrations for any cell line.
-
Cell Line:PC3 (human prostate cancer), MCF-7 (human breast cancer)
-
Concentration:20 µM
-
Incubation Time:48 h prior to irradiation with 8 Gy; 24 h incubation post-irradiation
-
Result:Reduced PC3 cell G0/G1 phase fraction from 47.8% to 36.3% and increased G2/M phase fraction from 46.1% to 56.8% when combined with 8 Gy irradiation compared to irradiation alone.
Reduced MCF-7 cell G0/G1 phase fraction from 43.3% to 41.7% and increased G2/M phase fraction from 43.8% to 48.4% when combined with 8 Gy irradiation compared to irradiation alone.
Had no significant effect on cell cycle distribution compared to control when used alone in either cell line.
Chemical Information
-
Appearance Solid
-
Molecular Weight 440.38
-
Formula C18H19F3N6O4
-
Color White to off-white
-
SMILES
O[C@H]1C[C@@H](O[C@@H]1CO)N2C(NCC3=CC=C(OC(F)(F)F)C=C3)=NC4=C(N=CN=C42)N
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvent & Solubility
In Vitro:
DMSO : 100 mg/mL (227.08 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.68 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (276 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2708 mL | 11.3538 mL | 22.7077 mL | 56.7692 mL |
| 5 mM | 0.4542 mL | 2.2708 mL | 4.5415 mL | 11.3538 mL | |
| 10 mM | 0.2271 mL | 1.1354 mL | 2.2708 mL | 5.6769 mL | |
| 15 mM | 0.1514 mL | 0.7569 mL | 1.5138 mL | 3.7846 mL | |
| 20 mM | 0.1135 mL | 0.5677 mL | 1.1354 mL | 2.8385 mL | |
| 25 mM | 0.0908 mL | 0.4542 mL | 0.9083 mL | 2.2708 mL | |
| 30 mM | 0.0757 mL | 0.3785 mL | 0.7569 mL | 1.8923 mL | |
| 40 mM | 0.0568 mL | 0.2838 mL | 0.5677 mL | 1.4192 mL | |
| 50 mM | 0.0454 mL | 0.2271 mL | 0.4542 mL | 1.1354 mL | |
| 60 mM | 0.0378 mL | 0.1892 mL | 0.3785 mL | 0.9462 mL | |
| 80 mM | 0.0284 mL | 0.1419 mL | 0.2838 mL | 0.7096 mL | |
| 100 mM | 0.0227 mL | 0.1135 mL | 0.2271 mL | 0.5677 mL |
dA-NHbenzylOCF3 Related Classifications
HY-176217 Related Classifications
Powered by Bioz